Published in J Hepatol on January 17, 2007
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer (2011) 1.59
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake. Am J Pathol (2008) 1.33
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol (2008) 1.31
Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol (2011) 1.28
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol (2013) 1.22
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med (2008) 1.19
S6K1 deficiency protects against apoptosis in hepatocytes. Hepatology (2009) 1.11
Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol (2008) 1.09
Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol (2008) 1.03
Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer (2012) 0.98
Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One (2012) 0.96
Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol (2008) 0.95
Vascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in mice. Neoplasia (2011) 0.91
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol (2013) 0.91
Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma. Dig Dis Sci (2008) 0.89
Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol (2012) 0.87
Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol Int (2010) 0.84
Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma. United European Gastroenterol J (2013) 0.83
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
Evolving therapies in the treatment of hepatocellular carcinoma. Biologics (2008) 0.83
Interconnections between autophagy and the coagulation cascade in hepatocellular carcinoma. Cell Death Dis (2014) 0.83
mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment. Biomed Res Int (2014) 0.82
Liver Transplantation for HCC: A Review. Indian J Surg (2011) 0.82
Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma. Cancer Manag Res (2012) 0.81
Intussusceptive microvascular growth in human glioma. Clin Exp Med (2009) 0.81
Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report. World J Gastroenterol (2010) 0.81
Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. Mol Cancer Ther (2015) 0.81
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol (2013) 0.81
Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model. Mol Imaging Biol (2009) 0.79
Image-aided Suicide Gene Therapy Utilizing Multifunctional hTERT-targeting Adenovirus for Clinical Translation in Hepatocellular Carcinoma. Theranostics (2016) 0.77
Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer (2015) 0.77
Effect of combination of rapamycin and cisplatin on human cervical carcinoma Hela cells. Contemp Oncol (Pozn) (2013) 0.77
Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells. J Cancer Res Clin Oncol (2014) 0.77
Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Sci Rep (2016) 0.77
Hepatocellular carcinoma: Will novel targeted drugs really impact the next future? World J Gastroenterol (2016) 0.76
Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF‑1α expression in vivo. Mol Med Rep (2014) 0.76
Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Invest New Drugs (2015) 0.76
Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma. Oncotarget (2016) 0.75
Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma. Dig Dis Sci (2014) 0.75
Combination of Photon and Carbon Ion Irradiation with Targeted Therapy Substances Temsirolimus and Gemcitabine in Hepatocellular Carcinoma Cell Lines. Front Oncol (2017) 0.75
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget (2016) 0.75
OIP5, a target of miR-15b-5p, regulates hepatocellular carcinoma growth and metastasis through the AKT/mTORC1 and β-catenin signaling pathways. Oncotarget (2017) 0.75
Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells. Oncotarget (2016) 0.75
Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model. Lab Invest (2014) 0.75
Participation of aquaporin-1 in vascular changes and remodeling in cirrhotic liver. Med Mol Morphol (2013) 0.75
Locoregional and systemic therapy for hepatocellular carcinoma. J Gastrointest Oncol (2017) 0.75
Hypoxia as a target for drug combination therapy of liver cancer. Anticancer Drugs (2017) 0.75
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol (2009) 3.28
Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J (2003) 2.85
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74
Flow regulates arterial-venous differentiation in the chick embryo yolk sac. Development (2003) 2.43
Angiogenesis and hepatocellular carcinoma. J Hepatol (2004) 2.25
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11
Induction of severe systemic lupus erythematosus by TNF blockade and response to anti-IL-6 strategy. J Allergy Clin Immunol (2012) 2.09
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. J Hepatol (2012) 2.07
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica (2003) 1.97
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis (2013) 1.85
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev Dyn (2004) 1.74
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
Self-sufficient control of urate homeostasis in mice by a synthetic circuit. Nat Biotechnol (2010) 1.64
Reconstruction of the medial patellofemoral ligament using the adductor magnus tendon: an anatomic study. Arthroscopy (2011) 1.52
EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J (2006) 1.48
Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci U S A (2007) 1.43
Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction. Nucleic Acids Res (2002) 1.37
Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering. Biomaterials (2007) 1.34
Pulsatile shear and Gja5 modulate arterial identity and remodeling events during flow-driven arteriogenesis. Development (2010) 1.32
Design of custom-shaped vascularized tissues using microtissue spheroids as minimal building units. Tissue Eng (2006) 1.29
Intussusceptive angiogenesis and its role in vascular morphogenesis, patterning, and remodeling. Angiogenesis (2009) 1.24
Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther (2008) 1.24
Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. Clin Sci (Lond) (2009) 1.22
Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol (2011) 1.19
Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol (2005) 1.17
Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. Ann Surg (2002) 1.16
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res (2004) 1.14
The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci (2004) 1.14
Induction of vascular networks in adult organs: implications to proangiogenic therapy. Ann N Y Acad Sci (2003) 1.13
Regulation of Ca(2+) signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms. Hepatology (2002) 1.11
Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol (2008) 1.10
Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. Gastroenterology (2012) 1.09
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 1.09
VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med (2014) 1.08
Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.08
Postmortem angiography: review of former and current methods. AJR Am J Roentgenol (2007) 1.06
Intussusceptive angiogenesis--the alternative to capillary sprouting. Mol Aspects Med (2002) 1.06
Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther (2011) 1.06
Treatment of NASH with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol (2012) 1.06
Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. Oncol Rep (2002) 1.06
Making vascular networks in the adult: branching morphogenesis without a roadmap. Trends Cell Biol (2003) 1.05
Regenerative capacity of individual liver lobes in the microsurgical mouse model. Microsurgery (2006) 1.05
Postmortem angiography after vascular perfusion with diesel oil and a lipophilic contrast agent. AJR Am J Roentgenol (2006) 1.05
Anatomic considerations for the choice of surgical approach for hip resurfacing arthroplasty. Orthop Clin North Am (2005) 1.05
Estimation of central venous pressure by ultrasound. Resuscitation (2005) 1.05
Two-step postmortem angiography with a modified heart-lung machine: preliminary results. AJR Am J Roentgenol (2008) 1.05
Modulation of the natural killer cell KIR repertoire by cytomegalovirus infection. Eur J Immunol (2012) 1.04
MR motility imaging in Crohn's disease improves lesion detection compared with standard MR imaging. Eur Radiol (2010) 1.04
Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol (2008) 1.03
Combined femoral and obturator neuropathy caused by synovial cyst of the hip. Muscle Nerve (2005) 1.01
Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. Eur Heart J (2010) 1.01
VEGF profiling and angiogenesis in human microtissues. J Biotechnol (2005) 1.00
Caveolin-1 is required for signaling and membrane targeting of EphB1 receptor tyrosine kinase. J Cell Sci (2006) 1.00
Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging (2010) 1.00
Angiofil-mediated visualization of the vascular system by microcomputed tomography: a feasibility study. Microsc Res Tech (2008) 1.00
Ordering CT pulmonary angiography to exclude pulmonary embolism: defense versus evidence in the emergency room. Intensive Care Med (2012) 1.00
Excessive erythrocytosis in adult mice overexpressing erythropoietin leads to hepatic, renal, neuronal, and muscular degeneration. Am J Physiol Regul Integr Comp Physiol (2006) 0.98
Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization. J Biol Chem (2005) 0.98
EphB4 receptor tyrosine kinase transgenic mice develop glomerulopathies reminiscent of aglomerular vascular shunts. Mech Dev (2003) 0.97
Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLoS One (2013) 0.97
Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res (2007) 0.96
Tissue-transplant fusion and vascularization of myocardial microtissues and macrotissues implanted into chicken embryos and rats. Tissue Eng (2006) 0.95
Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer? Am J Pathol (2010) 0.95
Hit proteins, mitochondria and cancer. Biochim Biophys Acta (2011) 0.95
Extended preservation of rat liver graft by induction of heme oxygenase-1. Hepatology (2002) 0.95
Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. Gastroenterology (2006) 0.94
Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int (2007) 0.94
Microvascular growth, development, and remodeling in the embryonic avian kidney: the interplay between sprouting and intussusceptive angiogenic mechanisms. Microsc Res Tech (2005) 0.94
Expression of transforming growth factor-alpha, epidermal growth factor receptor and platelet-derived growth factors A and B in oropharyngeal cancers treated by curative radiation therapy. Radiother Oncol (2002) 0.93
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. Liver Int (2014) 0.93
Therapeutic protein transduction of mammalian cells and mice by nucleic acid-free lentiviral nanoparticles. Nucleic Acids Res (2006) 0.92
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. J Hepatol (2012) 0.92
Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the beta3 integrin subunit. Int J Oncol (2007) 0.92
Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver Int (2007) 0.92
Conditional human VEGF-mediated vascularization in chicken embryos using a novel temperature-inducible gene regulation (TIGR) system. Nucleic Acids Res (2003) 0.92
Angiogenesis in cancer - general pathways and their therapeutic implications. J BUON (2014) 0.92
Quantity of HLA-C surface expression and licensing of KIR2DL+ natural killer cells. Immunogenetics (2012) 0.92
Disruption of the histidine triad nucleotide-binding hint2 gene in mice affects glycemic control and mitochondrial function. Hepatology (2013) 0.91
A transgenic model for conditional induction and rescue of portal hypertension reveals a role of VEGF-mediated regulation of sinusoidal fenestrations. PLoS One (2011) 0.91
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology (2012) 0.90
Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int (2009) 0.90
Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol (2004) 0.89
FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature. J Clin Invest (2015) 0.89
VEGF over-expression in skeletal muscle induces angiogenesis by intussusception rather than sprouting. Angiogenesis (2012) 0.88